DroneShield Limited lost its momentum on Wednesday, the day after finding a place in the top gainers on the This comes a day after the Australian share market witnessed a decline as it ended the day on Tuesday (December 16, 2025) with the S&P/ASX 200 closing on the lower side, dropping 36.10 points, or 0.42%, to 8,598.90.ASX 200: Top gainers and losersOn the S&P/ASX 200, several stocks recorded notable gains and declines. Among the top performers, IGO Limited (IGO) led the board with a last price of $7.690 ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Telix Pharmaceuticals Ltd. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Telix securities between February 21, 2025, and August 28, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 9, 2026 [3]. - The lawsuit alleges that defendants made materially false and misleading statements regarding Telix's progress in prostate cancer therapeutic candidates and the quality of its supply chain [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class action settlements [4].

SAN DIEGO--(BUSINESS WIRE)---- $TLX #Telix--Robbins LLP: Company: Telix Pharmaceuticals Ltd. (NASDAQ: TLX) is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. What is the class period? February 21, 2025 - August 28, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or acquired Telix securities during the class p ...

We recently published 7 Best ASX Stocks to Buy Right Now.  Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the best ASX stocks. Telix Pharmaceuticals Limited (NASDAQ:TLX) is a biotechnology company developing treatments for ailments such as prostate and kidney cancer. The firm’s prostate cancer therapy candidate TLX591 is currently in a phase three study. On this front, Telix Pharmaceuticals Limited (NASDAQ:TLX) shared important news on December 8th when it announced that it had dosed the first patie ...

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. on behalf of investors who purchased securities during the specified class period, alleging misleading statements regarding the company's business and operations [1][3]. Company Overview - Telix Pharmaceuticals Ltd. is a biopharmaceutical company based in Melbourne, Australia, focusing on the development of radiopharmaceuticals for cancer treatment [2]. Allegations - The lawsuit claims that the defendants made false or misleading statements, including: - Materially overstated progress on prostate cancer therapeutic candidates [3]. - Exaggerated quality and performance of the company's supply chain and partners [3]. - Resulting statements about the company's business, operations, and prospects were allegedly false or lacked a reasonable basis [3]. Investor Information - Investors who purchased Telix securities during the class period have until January 9, 2026, to seek appointment as lead plaintiff representative [2].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Telix Pharmaceuticals Ltd. securities between February 21, 2025, and August 28, 2025, about the January 9, 2026, deadline to become a lead plaintiff in a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Telix securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court by January 9, 2026, to serve as lead plaintiff, representing other class members [3]. - The lawsuit alleges that defendants made materially false and misleading statements regarding Telix's progress in prostate cancer therapeutic candidates and the quality of its supply chain and partners [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to allegations of misleading statements and failure to disclose critical information regarding its prostate cancer therapeutic candidates, leading to significant investor losses [2][4]. Group 1: Allegations Against Telix Pharmaceuticals - The complaint alleges that Telix and its executives violated federal securities laws by making false and misleading statements about the progress of its prostate cancer therapeutic candidates [4]. - It is claimed that Telix materially overstated the quality of its supply chain and partners, resulting in misleading statements about its business operations and prospects [4]. - The lawsuit asserts that when the true details about Telix's situation became public, investors suffered damages [4]. Group 2: Impact on Stock Price - Following the announcement of a subpoena from the U.S. Securities and Exchange Commission regarding Telix's disclosures, the price of Telix's American Depositary Shares fell more than 13% over two trading sessions [5]. - On August 28, 2025, Telix disclosed receiving a Complete Response Letter from the FDA, which identified deficiencies in its product TLX250-CDx, causing the stock price to drop more than 21% over two trading sessions [6]. Group 3: Legal Proceedings - Investors who purchased Telix securities between February 21, 2025, and August 28, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][2]. - There is a deadline of January 9, 2026, for investors to seek the role of lead plaintiff in the federal securities class action against Telix [2][7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Telix Pharmaceuticals Ltd. securities between February 21, 2025, and August 28, 2025, about the upcoming lead plaintiff deadline for a securities class action lawsuit [1] Group 1: Class Action Details - Investors who bought Telix securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 9, 2026 [3] - The lawsuit alleges that defendants made materially false and misleading statements regarding Telix's progress in prostate cancer therapeutic candidates and the quality of its supply chain [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions of dollars for investors [4] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [4]

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team: ht ...

NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https ...